// Press Release
Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress WASHINGTON, D.C., April 25, 2019 /CNW Telbec/ – Medicago, a Canadian biotech company and global leader in the development and production of plant-derived vaccines, announced today that its proprietary plant-based production platform, Proficia® was named “Best New Vaccine Technology/platform” at the World Vaccine Congress in Washington, D.C., attended by 1,500 participants including key opinion leaders from the vaccine industry. The Vaccine Industry Excellence (ViE) Awards recognize the outstanding achievements of vaccine practitioners and stakeholders across the global vaccine industry. “It is very gratifying to see that our technology is again being recognized as innovative in our industry”, said Bruce Clark, President & Chief Executive Officer of Medicago. “Winning this award as the best new technology in the eyes of leading experts in the vaccine industry is an important validation of the value of our plant-based technology to vaccine and antibody development.” Developed in Quebec City, Medicago’s technology has the potential to rapidly respond to surging threats by producing vaccines or therapeutic antibodies in the face of an outbreak such as pandemic influenza. Our data has shown that the Proficia® platform can: Rapidly deliver a pandemic vaccine candidate in 5 to 6 weeks Accurately match the selected strain as a result of its recombinant technology Easily scale vaccine production as one plant or 10,000 plants require the same growth conditions Medicago’s platform versatility has been demonstrated for the production of vaccines and antibodies. In 2012, in the context of DARPA’s Blue Angel program, the company successfully proved its platform capacity to produce 10 million doses of a candidate H1N1 pandemic vaccine in one month at its manufacturing plant in North Carolina. Medicago’s influenza development program includes a pandemic, a seasonal and a universal flu vaccine. In addition to flu vaccines, in 2015, Medicago successfully completed a contract with the U.S. government (BARDA) to produce anti-Ebola antibodies. On top of this newly received award, Medicago’s platform Proficia® was awarded the “Game-changing Technology Award in 2014, by BIOTECanada”. This prize recognized an organization that had made a significant contribution to the biotech industry in Canada through the innovative plant-based vaccine production platform. In 2018, Medicago broke ground on the new $245 million manufacturing complex in Quebec City that will include the company’s headquarters, research and development as well as production facilities. The company plans to produce annually 40 to 50 million doses of quadrivalent vaccines against seasonal influenza. In 2019, Medicago will achieve a key milestone by completing Phase III clinical studies in adults and elderly subjects. About World Vaccine Congress The World Vaccine Congress remains the industry’s definitive vaccine industry event for major vaccine players. Officially the longest-running and largest vaccine industry event in North America, the World Vaccine Congress delivers a forum where the ever-changing dynamics of the vaccine industry are discussed and acted upon by the industry’s most senior figures. About Medicago Medicago is a Canadian clinical-stage biopharmaceutical company with more than 450 employees in Canada and the United States. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. Pour plus de détails : www.medicago.com SOURCE Medicago
Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress WASHINGTON, D.C., April 25, 2019 /CNW Telbec/ – Medicago, a Canadian biotech company and global leader in the development and production of plant-derived vaccines, announced today that its proprietary plant-based production platform, Proficia® was named “Best New Vaccine Technology/platform” at the World Vaccine Congress … Continue reading Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress WASHINGTON, D.C., April 25, 2019 /CNW Telbec/ – Medicago, a Canadian biotech company and global leader in the development and production of plant-derived vaccines, announced today that its proprietary plant-based production platform, Proficia® was named “Best New Vaccine Technology/platform” at the World Vaccine Congress in Washington, D.C., attended by 1,500 participants including key opinion leaders from the vaccine industry. The Vaccine Industry Excellence (ViE) Awards recognize the outstanding achievements of vaccine practitioners and stakeholders across the global vaccine industry. “It is very gratifying to see that our technology is again being recognized as innovative in our industry”, said Bruce Clark, President & Chief Executive Officer of Medicago. “Winning this award as the best new technology in the eyes of leading experts in the vaccine industry is an important validation of the value of our plant-based technology to vaccine and antibody development.” Developed in Quebec City, Medicago’s technology has the potential to rapidly respond to surging threats by producing vaccines or therapeutic antibodies in the face of an outbreak such as pandemic influenza. Our data has shown that the Proficia® platform can: Rapidly deliver a pandemic vaccine candidate in 5 to 6 weeks Accurately match the selected strain as a result of its recombinant technology Easily scale vaccine production as one plant or 10,000 plants require the same growth conditions Medicago’s platform versatility has been demonstrated for the production of vaccines and antibodies. In 2012, in the context of DARPA’s Blue Angel program, the company successfully proved its platform capacity to produce 10 million doses of a candidate H1N1 pandemic vaccine in one month at its manufacturing plant in North Carolina. Medicago’s influenza development program includes a pandemic, a seasonal and a universal flu vaccine. In addition to flu vaccines, in 2015, Medicago successfully completed a contract with the U.S. government (BARDA) to produce anti-Ebola antibodies. On top of this newly received award, Medicago’s platform Proficia® was awarded the “Game-changing Technology Award in 2014, by BIOTECanada”. This prize recognized an organization that had made a significant contribution to the biotech industry in Canada through the innovative plant-based vaccine production platform. In 2018, Medicago broke ground on the new $245 million manufacturing complex in Quebec City that will include the company’s headquarters, research and development as well as production facilities. The company plans to produce annually 40 to 50 million doses of quadrivalent vaccines against seasonal influenza. In 2019, Medicago will achieve a key milestone by completing Phase III clinical studies in adults and elderly subjects. About World Vaccine Congress The World Vaccine Congress remains the industry’s definitive vaccine industry event for major vaccine players. Officially the longest-running and largest vaccine industry event in North America, the World Vaccine Congress delivers a forum where the ever-changing dynamics of the vaccine industry are discussed and acted upon by the industry’s most senior figures. About Medicago Medicago is a Canadian clinical-stage biopharmaceutical company with more than 450 employees in Canada and the United States. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. Pour plus de détails : www.medicago.com SOURCE Medicago
Spectrum Cannabis and the Arthritis Society Team Up to Launch Arthritis Talks, A National Symposium Series for Patients
Spectrum Cannabis and the Arthritis Society Team Up to Launch Arthritis Talks, A National Symposium Series for Patients SMITHS FALLS, ON and TORONTO, April 25, 2019 /CNW/ – Spectrum Cannabis, the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to announce a partnership with the Arthritis Society to raise awareness and educate … Continue reading Spectrum Cannabis and the Arthritis Society Team Up to Launch Arthritis Talks, A National Symposium Series for Patients
Genome BC Invests $1 Million in Funding to Innovative Medical Diagnostics Company
Genome BC Invests $1 Million in Funding to Innovative Medical Diagnostics Company LightIntegra’s ThromboLUX test for blood platelet activation status could improve efficacy of platelet transfusions VANCOUVER, April 25, 2019 /CNW/ – Genome BC is pleased to announce $1 million in funding to LightIntegra Technology (LIT). LIT has developed the first analyzer to provide a … Continue reading Genome BC Invests $1 Million in Funding to Innovative Medical Diagnostics Company
Canada’s Largest Private Funder of Vision Research Calls for National Strategy to Tackle Emerging Vision Health Care Crisis
Canada’s Largest Private Funder of Vision Research Calls for National Strategy to Tackle Emerging Vision Health Care Crisis VANCOUVER, April 25, 2019 /CNW/ – Fighting Blindness Canada (FBC) is warning that Canada is facing an emerging vision health care crisis that, if not addressed, will see the number of people living with blindness double by 2031. Blindness is … Continue reading Canada’s Largest Private Funder of Vision Research Calls for National Strategy to Tackle Emerging Vision Health Care Crisis
The Growing Wellness Holiday Demand for Health-Conscious Men
The Growing Wellness Holiday Demand for Health-Conscious Men The 10th to the 16th of June marks both Men’s Health Week and Father’s Day, So whether you’re travelling alone, looking for some peace and quiet, or if you’ve got a fitness boot-camp in mind, Health and Fitness Travel, the wellness holiday specialists has you covered. What better time to take care of the men in your … Continue reading The Growing Wellness Holiday Demand for Health-Conscious Men
Intermittent fasting has been shown to be an effective method of controlling blood glucose levels in men at risk of developing type 2 diabetes.
Intermittent fasting has been shown to be an effective method of controlling blood glucose levels in men at risk of developing type 2 diabetes. Researchers from the University of Adelaide and the South Australian Health and Medical Research Institute (SAHMRI) assessed the effects of time-restricted eating (TRE) in 15 men for one week.The men, aged 30-70 years and with … Continue reading Intermittent fasting has been shown to be an effective method of controlling blood glucose levels in men at risk of developing type 2 diabetes.
Runners are lacing up their shoes in support of charities, as part the Banque Scotia 21k de Montréal
Runners are lacing up their shoes in support of charities, as part the Banque Scotia 21k de Montréal 80 charities will benefit from the annual Scotiabank Charity Challenge MONTREAL, April 24, 2019 /CNW/ – At the 2019 Banque Scotia 21k de Montréal, many of the runners will have two important goals, finishing the race and raising … Continue reading Runners are lacing up their shoes in support of charities, as part the Banque Scotia 21k de Montréal
Testosterone For Women, EstrogenFor Men? Wrong Levels Bring ProblemsBy Don Colbert, M.D.
Testosterone For Women, EstrogenFor Men? Wrong Levels Bring ProblemsBy Don Colbert, M.D. You don’t normally think of women needing testosterone and men needing estrogen. But when those levels drop for women and men, respectively, or are way out of balance, a wide range of symptoms may be suffered. Fortunately, there are ways to correct those levels … Continue reading Testosterone For Women, EstrogenFor Men? Wrong Levels Bring ProblemsBy Don Colbert, M.D.
Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA™ (nusinersen)
Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA™ (nusinersen) The Government of the province of Saskatchewan has informed treating physicians that it will grant access to SPINRAZA™ to patients living with Spinal Muscular Atrophy (SMA) Saskatchewan is the second province after the province of Quebec to grant … Continue reading Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA™ (nusinersen)
Rice U. device would help fix fractured bones
Rice U. device would help fix fractured bonesEngineering students use magnets, tracking sensor to drill bone, insert screws in just the right spot HOUSTON – (April 22, 2019) – Threading a needle is hard, but at least you can see it. Think about how challenging it must be to thread a screw through a rod inside … Continue reading Rice U. device would help fix fractured bones
